| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 983,536 | 1,305,512* | 756,217 | NaN |
| Cost of revenue | 698,049 | 1,143,889.5* | 815,871 | NaN |
| Gross profit (gain) | 285,487 | 161,622.5* | -59,654 | NaN |
| Selling expenses | 95,598 | 128,058* | 78,041 | NaN |
| General and administrative expenses | 1,226,272 | 1,243,605.5* | 424,827 | NaN |
| Research and development expenses | 83,762 | 176,039* | 40,321 | NaN |
| Credit losses | -2,881 | -36,986.5* | 25,302 | NaN |
| Total operating expenses | 1,402,751 | 1,510,716* | 568,491 | NaN |
| Loss from operations | -1,117,264 | -1,349,093.5* | -628,145 | NaN |
| Research and development subsidy | NaN | 155,736.5* | 415 | NaN |
| Interest income | 147 | 1,121* | 294 | NaN |
| Interest expense | 26,031 | 29,899* | 24,046 | NaN |
| Income tax expense | NaN | NaN | NaN | 0 |
| Net other expense | -25,884 | 126,958.5* | -23,337 | NaN |
| Loss before income taxes | -1,143,148 | -1,222,135 | -651,482 | -528,367 |
| Net loss | -1,143,148 | -1,222,135 | -651,482 | -528,367 |
| Other comprehensive income - foreign currency translation adjustment | 433,586 | 177,890 | 57,335 | 20,263 |
| Comprehensive loss | -709,562 | -1,044,245 | -594,147 | -508,104 |
| Basic EPS | -0.04 | -0.154 | -0.17 | -0.16 |
| Diluted EPS | -0.04 | -0.185* | -0.17 | -0.16 |
| Basic Average Shares | 25,602,002 | 6,767,710 | 3,874,085 | 3,262,002 |
| Diluted Average Shares | 25,602,002 | NaN | NaN | NaN |
CHINA PHARMA HOLDINGS, INC. (CPHI)
CHINA PHARMA HOLDINGS, INC. (CPHI)